In Latin America, Grünenthal is further strengthening the business in these fast-growth emerging markets with selected acquisitions and licensing deals. Following the successful acquisition and integration of the Brazilian company Selfarma in 2011, Grünenthal announced in June 2012 an exclusive agreement with US-based Horizon Pharma for the commercialization of DUEXIS ® in Latin America. The company's current leading market position in Latin America is mainly based on a strong portfolio in pain, Grünenthal's global core competence along with strong regional products.More information about Grünenthal: http://www.grunenthal.com
GrÃ¼nenthal Appoints Oscar Ferenczi To Lead Its Latin America Business
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.